Quantitative analysis of organ tissue damage after septic shock

American Surgeon

Volumn 73, Issue 3, 2007, Pages 243-248

  Martens, M ^a,b   Kumar, M M ^a   Kumar, S ^a   Goldenberg, M ^a   Kawata, M ^a   Pennycooke, O ^a   Strande, L ^a   Hadeed, J ^a   Camacho, J ^a   Hewitt, C ^a   Slotman, G J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROMONAS HYDROPHILA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIGITAL IMAGING; GENERAL ANESTHESIA; HEART; KIDNEY PARENCHYMA; LIVER; LUNG ALVEOLUS WALL; LUNG HEMORRHAGE; LUNG PARENCHYMA; NONHUMAN; OPTICAL DENSITY; QUANTITATIVE ANALYSIS; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; SWINE; TISSUE INJURY; ANIMAL; BIOPSY; CELL NUCLEUS; CYTOPLASM; DISEASE MODEL; GRAM NEGATIVE INFECTION; HEART MUSCLE; HOSPITALIZATION; KIDNEY; LUNG; PATHOLOGY;

AEROMONAS HYDROPHILA; ANIMALS; BIOPSY; CELL NUCLEUS; CYTOPLASM; DISEASE MODELS, ANIMAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY; LIVER; LUNG; MYOCARDIUM; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SWINE;

EID: 34147189049     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Balk RA. Optimum treatment of severe sepsis and septic shock: Evidence in support of the recommendations. Dis Mon 2004;50:168-213.
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for organ sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1844-55.
3. Bone RC, Grodzin CJ, Balk RA. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997;112:235-43.
4. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
5. O'Brien JM Jr, Abraham E. New approaches to the treatment of sepsis. Clin Chest Med 2003;24:521-48.
6. Abraham E, Anzueto A, Gutierrez G, et al. Double blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in the treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:20-33.
7. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277:1531-8.
8. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized double-blind, placebo-controlled multicenter phase II trial with 1342 patients. Crit Care Med 2001;29:503-10.
9. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: IIIa phase, randomized, double-blind, placebo controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115-24.
10. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995;274:968-74.
11. Glauser MP. Pathophysiologic basis of sepsis: Considerations for future strategies of intervention. Crit Care Med 2000;28(Suppl):S4-7.
12. Wenzel RP, Edmond MB. Severe sepsis: National estimates. Crit Care Med 2001;29:1472-4.
13. Young LS. Sepsis syndrome. In: Mandell G, Bennett J, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th Ed, Vol. 1. New York: Churchill Livingstone, 2000, pp 806-17.
14. Parker MM, Parrillo JE. Septic shock. Hemodynamics and pathogenesis. JAMA 1983;250:3324-7.
15. Hersch M, Gnidec AA, Bersten AD, et al. Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery 1990;107:397-410.
16. Edelson JD, Vadas P, Villar J, et al. Acute lung injury induced by phospholipase A2. Structural and functional changes. Am Rev Resoir Dis 1991;143:1102-9.
17. Tran HS, Quinn JV, Puc MM, et al. The cardiovascular hemodynamics and leukotriene kinetics during prostacyclin and anti-prostacyclin antibody infusions in septic shock. Shock 2000;13:478-84.
18. Feigal D, Black D, Brady D, et al. Designing Clinical Research. Planning for Data Management and Analysis. Baltimore: Williams & Wilkins, 1988, pp 59-170.
19. von Graevenitz A, Mensch AH. The genus aeromonas in human bacteriology. N Engl J Med 1968;278:245-9.
20. Woolley DS, Puglisi RN, Quinn JV, Slotman GJ. Platelet activating factor mediates cardiopulmonary dysfunction during graded bacteremic shock. J Trauma Injury Crit Care 1996;41:291-7.
21. Saeki H, Matsuda N, Tamura T, Masuda N, Yonei A. A case of severe septicemia due to Aeromonas hydrophila. 2002;103(1):53-7.
22. Caruana JA, Montes M, Camara DS, et al. Functional and histopathologic changes in the liver during sepsis. Surg Gynecol Obstet 1982;154:653-6.
23. Kumar V, Abbas AK, Fausto N. Robbins and Cotran: Pathologic Basis of Disease, 7th Ed. Philadelphia: Elsevier-Saunders, 1999, Chapters 15, 18, and 20.
24. Travis, William D, et al. Non-Neoplastic Disorders of the Lower Respiratory Tract. Washington, D.C.: American Registry of Pathology, 2002, Chapter 3.
25. Hepinstall RH. Pathology of the Kidney, 4th Ed. Boston: Little, Brown and Company, 1992, Chapter 18.
26. Tisher CC, Brenn BM. Renal Pathology: With Clinical and Functional Correlations, 2nd Ed. Philadelphia: J.B. Lippincott Company, 1994, Chapter 24.
27. Ceydeli A, Condon MR, Siegel JH. The septic abscess wall: A cytokine-generating organ associated with portal venous cytokinemia, hepatic outflow fibrosis, sinusoidal congestion, inflammatory cell sequestration, hepatocellular lipid deposition, and focal cell death. Shock 2003;20:74-84.